Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.7% on Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was down 3.7% on Friday after an insider sold shares in the company. The stock traded as low as $7.15 and last traded at $7.29. Approximately 3,043,775 shares changed hands during mid-day trading, a decline of 50% from the average daily volume of 6,103,637 shares. The stock had previously closed at $7.57.

Specifically, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $7.21, for a total value of $43,260.00. Following the transaction, the chief operating officer now owns 535,457 shares in the company, valued at $3,860,644.97. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, COO Tina Marriott sold 6,000 shares of the stock in a transaction that occurred on Thursday, June 27th. The shares were sold at an average price of $7.21, for a total value of $43,260.00. Following the transaction, the chief operating officer now directly owns 535,457 shares in the company, valued at $3,860,644.97. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $8.82, for a total transaction of $100,962.54. Following the completion of the transaction, the director now directly owns 7,241,308 shares in the company, valued at $63,868,336.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 258,806 shares of company stock valued at $2,158,997. Company insiders own 15.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Needham & Company LLC restated a “buy” rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday. KeyCorp boosted their price objective on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Monday, March 4th.

Recursion Pharmaceuticals Price Performance

The business has a 50 day simple moving average of $8.84 and a 200-day simple moving average of $9.92. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of -4.69 and a beta of 0.86.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.04. The business had revenue of $13.80 million during the quarter, compared to analyst estimates of $11.10 million. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. Recursion Pharmaceuticals’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.34) EPS. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.6 earnings per share for the current year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Mubadala Investment Co PJSC acquired a new position in Recursion Pharmaceuticals in the 4th quarter worth $128,041,000. Citigroup Inc. grew its holdings in shares of Recursion Pharmaceuticals by 165.3% during the third quarter. Citigroup Inc. now owns 470,512 shares of the company’s stock worth $3,599,000 after buying an additional 293,174 shares in the last quarter. Gladstone Institutional Advisory LLC bought a new position in shares of Recursion Pharmaceuticals during the fourth quarter worth about $133,000. Norges Bank acquired a new stake in Recursion Pharmaceuticals in the 4th quarter valued at approximately $34,825,000. Finally, UBS Group AG lifted its stake in Recursion Pharmaceuticals by 103.1% in the 3rd quarter. UBS Group AG now owns 342,679 shares of the company’s stock valued at $2,621,000 after acquiring an additional 173,954 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.